Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry
European Respiratory Journal · 2023-02 · 61 (2) · 2201336
DOI: 10.1183/13993003.01336-2022 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Respiratory Journal, online erschienen am 30.09.2022. Verfasst von Martin Metzenmacher und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis, Takeda Pharmaceutical Company, Bristol-Myers Squibb.
Abstract (Originalsprache)
Introduction
Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care.
Methods
Prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models.
Results
Current M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, Essen, Germany.
- Department of Haematology and Oncology, University Dept Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany.
- Interdisziplinäres Studienzentrum mit ECTU/Translationale Onkologie, Comprehensive Cancer Center, Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
- Pneumologie, Infektiologie, Internistische Intensivmedizin, Klinik Nord im Klinikum Dortmund, Dortmund, Germany.
- Pneumologie, Thorakale Onkologie, Palliativmedizin, Infektiologie, SHG Kliniken Völklingen, Völklingen, Germany.
Förderung
- Novartis
- Takeda Pharmaceutical Company
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Merck Sharp and Dohme
- Roche
- Janssen-Cilag
- AstraZeneca
Zitieren
APA
Metzenmacher, M., Griesinger, F., Hummel, H. D., Elender, C., Schäfer, H., de Wit, M., Kaiser, U., Kern, J., Jänicke, M., Spring, L., Zacharias, S., Kaiser-Osterhues, A., Groth, A., Hipper, A., Zaun, G., Dörfel, S., Güldenzoph, B., Müller, L., Uhlig, J., …, & CRISP Registry Group (2023). Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. European Respiratory Journal, 61(2), 2201336. https://doi.org/10.1183/13993003.01336-2022
Vancouver
Metzenmacher M, Griesinger F, Hummel HD, Elender C, Schäfer H, de Wit M, et al. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. European Respiratory Journal. 2023;61(2):2201336. doi:10.1183/13993003.01336-2022
BibTeX
@article{Metzenmacher2023,
author = {Metzenmacher, Martin and Griesinger, Frank and Hummel, Horst-Dieter and Elender, Corinna and Schäfer, Harald and de Wit, Maike and Kaiser, Ulrich and Kern, Jens and Jänicke, Martina and Spring, Lisa and Zacharias, Stefan and Kaiser-Osterhues, Anja and Groth, Annika and Hipper, Annette and Zaun, Gregor and Dörfel, Steffen and Güldenzoph, Björn and Müller, Lothar and Uhlig, Jens and Thomas, Michael and Sebastian, Martin and Eberhardt, Wilfried E E and CRISP Registry Group, CRISP Registry Group},
title = {Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry},
journal = {European Respiratory Journal},
year = {2023},
volume = {61},
number = {2},
pages = {2201336},
doi = {10.1183/13993003.01336-2022}
}
EUVIMED